BR112015017403A2 - biomarcadores de terapia de combinação de anti-tnf e anti-il17 para doença inflamatória - Google Patents

biomarcadores de terapia de combinação de anti-tnf e anti-il17 para doença inflamatória

Info

Publication number
BR112015017403A2
BR112015017403A2 BR112015017403A BR112015017403A BR112015017403A2 BR 112015017403 A2 BR112015017403 A2 BR 112015017403A2 BR 112015017403 A BR112015017403 A BR 112015017403A BR 112015017403 A BR112015017403 A BR 112015017403A BR 112015017403 A2 BR112015017403 A2 BR 112015017403A2
Authority
BR
Brazil
Prior art keywords
tnf
inflammatory disease
combination therapy
biomarkers
therapy biomarkers
Prior art date
Application number
BR112015017403A
Other languages
English (en)
Inventor
A Cuff Carolyn
W Voss Jeffrey
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of BR112015017403A2 publication Critical patent/BR112015017403A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4 or KC
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

resumo “biomarcadores de terapia de combinação de anti-tnf e anti-il17 para doença inflamatória” a presente invenção proporciona métodos for prever a eficácia de terapias de combinação de anti-tnf e anti-il17 no tratamento de um indivíduo que sofre a partir de doença inflamatória por determinar o nível de marcadores cxcl1 e/ou cxcl5 em uma amostra derivada do indivíduo.
BR112015017403A 2013-01-21 2014-01-21 biomarcadores de terapia de combinação de anti-tnf e anti-il17 para doença inflamatória BR112015017403A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361754917P 2013-01-21 2013-01-21
PCT/US2014/012364 WO2014113804A1 (en) 2013-01-21 2014-01-21 Anti-tnf and anti-il17 combination therapy biomarkers for inflammatory disease

Publications (1)

Publication Number Publication Date
BR112015017403A2 true BR112015017403A2 (pt) 2017-11-21

Family

ID=50073489

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015017403A BR112015017403A2 (pt) 2013-01-21 2014-01-21 biomarcadores de terapia de combinação de anti-tnf e anti-il17 para doença inflamatória

Country Status (10)

Country Link
US (1) US20140205613A1 (pt)
EP (1) EP2946214A1 (pt)
JP (1) JP2016506720A (pt)
CN (1) CN105190314A (pt)
AU (1) AU2014207321A1 (pt)
BR (1) BR112015017403A2 (pt)
CA (1) CA2897997A1 (pt)
MX (1) MX2015009392A (pt)
TW (1) TW201514310A (pt)
WO (1) WO2014113804A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150291689A1 (en) * 2014-03-09 2015-10-15 Abbvie, Inc. Compositions and Methods for Treating Rheumatoid Arthritis
WO2015191783A2 (en) * 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
RU2609627C2 (ru) * 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
AU2016208161B2 (en) * 2015-01-12 2020-01-16 Affibody Ab IL-17A-binding polypeptides
US20160244520A1 (en) * 2015-01-24 2016-08-25 Abbvie Inc. Compositions and methods for treating psoriatic arthritis
WO2017060242A1 (en) * 2015-10-05 2017-04-13 Ucb Biopharma Sprl Molecular signatures for use in diagnosis and response to treatment analysis of autoimmune diseases
CN106119348B (zh) * 2016-06-27 2018-02-23 中南大学湘雅医院 一种以非编码lnc‑CXCL1及编码基因cxcl1组合为检测或诊断筛查标志物的重症肌无力检测试剂盒及应用
CN107860830A (zh) * 2017-10-10 2018-03-30 暨南大学 一种寻常型银屑病血浆中生物标志物在其靶向药物的应用
CN107661501B (zh) * 2017-11-03 2020-04-28 中山大学孙逸仙纪念医院 一种治疗强直性脊柱炎的药物组合物、药物靶点及其应用
CN109796534B (zh) * 2017-11-16 2021-08-10 北京比洋生物技术有限公司 抗il-17抗体/tnfr ecd融合蛋白及其用途
AU2019417313B2 (en) * 2018-12-26 2023-01-19 Colgate-Palmolive Company Biomarkers of neutrophil deregulation as diagnostic for gingivitis
US20230227536A1 (en) * 2020-06-18 2023-07-20 Kyoto University Immunogenicity-reduced low-molecular antibody and method for producing same
CN116769027B (zh) * 2023-06-09 2023-12-01 康元医疗科技(大连)有限公司 一种抗il-17纳米抗体、多肽及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
DE69233331T3 (de) 1991-11-22 2007-08-30 Affymetrix, Inc., Santa Clara Kombinatorische Strategien zur Polymersynthese
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
ATE291097T1 (de) 1997-10-31 2005-04-15 Affymetrix Inc A Delaware Corp Expressionsprofile in adulten und fötalen organen
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
RU2015132478A (ru) 2009-03-05 2015-12-10 Эббви Инк. Связывающие il-17 белки
AU2012253422B2 (en) * 2011-05-10 2015-08-13 Société des Produits Nestlé S.A. Methods of disease activity profiling for personalized therapy management

Also Published As

Publication number Publication date
EP2946214A1 (en) 2015-11-25
WO2014113804A1 (en) 2014-07-24
AU2014207321A1 (en) 2015-07-23
MX2015009392A (es) 2015-10-15
US20140205613A1 (en) 2014-07-24
JP2016506720A (ja) 2016-03-07
CN105190314A (zh) 2015-12-23
WO2014113804A9 (en) 2015-07-09
TW201514310A (zh) 2015-04-16
CA2897997A1 (en) 2014-07-24

Similar Documents

Publication Publication Date Title
BR112015017403A2 (pt) biomarcadores de terapia de combinação de anti-tnf e anti-il17 para doença inflamatória
BR112017009159A2 (pt) métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40
BR112017028353A2 (pt) anticorpos para cd40 com atividade agonista melhorada
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
PH12016500302A1 (en) Compositions and method for treating complement-associated conditions
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112015023120A2 (pt) método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
AR084831A1 (es) Terapia anticancer mediante inhibidores de quinasa
EA201301180A1 (ru) Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой
EA201490030A1 (ru) Соединения, ингибирующие металлоферменты
PH12020551683A1 (en) Biomarkers for graft-versus-host disease
BR112014031365A2 (pt) métodos de detectar doenças ou condições
MX358541B (es) Metodos para predecir el riesgo de desarrollar hipertension.
BR112012019459A2 (pt) identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase.
BR112014007485A2 (pt) biomarcadores preditivos de sensibilidade a tratamento com ativador de receptor de acetilcolina nicotínico alfa 7
WO2011154139A3 (en) Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
BR112013021350A2 (pt) anticorpo e antígeno reconhecido de células iniciadoras de tumor e o uso destes
BR112016007864A2 (pt) método para a prognose e tratamento de metástase de câncer
EA201590024A1 (ru) Способы определения заболеваний или состояний с применением циркулирующих болезненных клеток
MX2019003569A (es) Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos.
MX2020006388A (es) Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea.
BR112015004653A2 (pt) método diagnóstico e terapêutico de câncer de moléculas alvo expressas em células-tronco cancerígenas
WO2014169011A3 (en) Methods for treating immune diseases
WO2015036643A3 (es) Marcador para predecir metástasis del cáncer de mama
RU2013135809A (ru) Способ прогнозирования эффективности химиотерапии у больных со злокачественными новообразованиями эпителиальных тканей

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2447 DE 28-11-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.